REGENXBIO’s (RGNX) “Outperform” Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of REGENXBIO (NASDAQ:RGNX) in a research note published on Tuesday,Benzinga reports. They currently have a $30.00 price objective on the biotechnology company’s stock.

A number of other equities research analysts have also commented on the stock. Chardan Capital restated a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a report on Wednesday, November 20th. Raymond James reissued an “outperform” rating and issued a $18.00 price target on shares of REGENXBIO in a research note on Thursday, October 10th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective on shares of REGENXBIO in a research report on Wednesday, January 15th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $22.00 target price on shares of REGENXBIO in a research report on Friday, November 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, REGENXBIO has an average rating of “Moderate Buy” and a consensus target price of $34.82.

REGENXBIO Stock Performance

Shares of RGNX stock opened at $7.95 on Tuesday. REGENXBIO has a 52 week low of $6.56 and a 52 week high of $28.80. The company’s 50 day moving average price is $8.52 and its two-hundred day moving average price is $10.42. The company has a market capitalization of $393.84 million, a P/E ratio of -1.58 and a beta of 1.28.

Hedge Funds Weigh In On REGENXBIO

A number of hedge funds have recently bought and sold shares of the company. FMR LLC lifted its position in shares of REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares in the last quarter. nVerses Capital LLC lifted its position in shares of REGENXBIO by 183.3% during the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after buying an additional 2,200 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of REGENXBIO by 273.1% during the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after buying an additional 2,510 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of REGENXBIO by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock worth $100,000 after buying an additional 3,720 shares during the last quarter. Finally, Erste Asset Management GmbH bought a new position in shares of REGENXBIO in the third quarter valued at approximately $140,000. 88.08% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.